


Amendments to the Claims

The following listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A compound according to ~~Formula I~~ Formula IA:



wherein $[[,]]$:

~~A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;~~

A¹ is aryl or heteroaryl and x is 0, 1, 2, 3, 4 or 5;

~~B is substituted aryl or substituted or unsubstituted heteroaryl;~~

either B¹ is aryl and y is 1, 2, 3, 4 or 5, or B¹ is heteroaryl and y is 0, 1, 2, 3, 4 or 5;

provided that x does not exceed the number of substitutable positions of the ring to which each R^a is attached; and y does not exceed number of substitutable positions of the ring to which each R^b is attached;

n is 1;

R¹ is -H, -(C₁-C₈)hydrocarbyl, -CN, -CO₂(C₁-C₆)alkyl or halo(C₁-C₆)alkyl;

the configuration of the substituents on the carbon-carbon double bond is either *E*- or *Z*-;

the configuration of the substituents on the sulfoxide sulfur atom is R-, S- or any mixture of R- and S-;

each R^a is independently selected from the group consisting of halogen; -(C₁-C₈)hydrocarbyl, -C(=O)R², -NR²₂, -NHC(=O)R³, -NHSO₂R³, -NHR⁴, -NHCR²R⁴C(=O)R⁶, -C(=O)OR², -C(=O)NHR²; -NO₂, -CN, -OR², -P(=O)(OH)₂, dimethylamino(C₂-C₆ alkoxy), -NHC(=NH)NHR², -(C₁-C₆)haloalkyl, -(C₁-C₆)haloalkoxy and -N=CH-R⁷;

each R^b attached to aryl is independently selected from the group consisting of -C(=O)R², halogen, -NO₂, -CN, -OR², -C(=O)OR², -NR²₂, (C₁-C₆)haloalkyl and (C₁-C₆)haloalkoxy;

each R^b attached to heteroaryl is independently selected from the group consisting of -(C₁-C₈)hydrocarbyl, -C(=O)R², halogen, -NO₂, -CN, -OR², -C(=O)OR², -NR²₂, (C₁-C₆)haloalkyl and (C₁-C₆)haloalkoxy;

each R² is independently selected from the group consisting of -H and -(C₁-C₈)hydrocarbyl;

each R³ is independently selected from the group consisting of -H, -(C₁-C₈)hydrocarbyl, -O(C₁-C₈)hydrocarbyl, substituted and unsubstituted aryl, substituted heterocyclyl(C₁-C₃)alkyl, heteroaryl(C₁-C₃)alkyl, -(C₂-C₁₀)heteroalkyl, -(C₁-C₆)haloalkyl, -CR²R⁴NHR⁵, -N(R²)₂, -(C₁-C₃)alkyleneNH₂, -(C₁-C₃)alkylene-N(CH₃)₂, -(C₁-C₃)perfluoroalkylene-N(CH₃)₂, -(C₁-C₃)alkylene-N⁺((C₁-C₃)alkyl)₃, -(C₁-C₃)alkylene-N⁺(CH₂CH₂OH)₃, -(C₁-C₃)alkylene-OR², -(C₁-C₄)alkylene-CO₂R², -(C₁-C₄)alkylene-C(=O)halogen, halo(C₁-C₃)alkyl-, -(C₁-C₃)alkylene-C(=O)(C₁-C₃)alkyl, and -(C₁-C₄)perfluoroalkylene-CO₂R²;

each R⁴ is independently selected from the group consisting of -H, -(C₁-C₆)alkyl, -(CH₂)₃-NH-C(NH₂)(=NH), -CH₂C(=O)NH₂, -CH₂COOH, -CH₂SH, -(CH₂)₂C(=O)-NH₂, -(CH₂)₂COOH, -CH₂-(2-imidazolyl), -(CH₂)₄-NH₂, -(CH₂)₂-S-CH₃, phenyl, -CH₂-phenyl, -CH₂-OH, -CH(OH)-CH₃, -CH₂-(3-indolyl), and -CH₂-(4-hydroxyphenyl);

each R⁵ is independently selected from the group consisting of -H and a carboxy terminally linked peptidyl residue containing from 1 to 3 amino acids in which the


terminal amino group of the peptidyl residue is present as a functional group selected from the group consisting of $-\text{NH}_2$ and $-\text{NHC}(=\text{O})(\text{C}_1\text{-C}_6)\text{alkyl}$, $-\text{NH}(\text{C}_1\text{-C}_6)\text{alkyl}$, $-\text{N}(\text{C}_1\text{-C}_6\text{ alkyl})_2$ and $-\text{NHC}(=\text{O})\text{O}(\text{C}_1\text{-C}_7)\text{hydrocarbonyl}$;

each R^6 is independently selected from the group consisting of $-\text{OR}^2$ and an *N*-terminally linked peptidyl residue containing from 1 to 3 amino acids in which the terminal carboxyl group of the peptidyl residue is present as a functional group selected from the group consisting of $-\text{CO}_2\text{R}^2$ and $-\text{C}(=\text{O})\text{NR}^2$; and

each R^7 is independently selected from the group consisting of substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl;


* indicates that, when R^1 is other than $-\text{H}$, the configuration of the substituents on the designated carbon atom is R-, S- or any mixture of R- and S-; or a salt of such a compound.

2. (currently amended) A compound according to claim 1 of Formula Iz IAz:




or a salt thereof.

3. (currently amended) A compound according to claim 1 of the Formula ~~Ie~~ IAe:




or a salt thereof.

4. (canceled)
5. (currently amended) A compound according to claim [[4]] 1, or a salt thereof, wherein the sum of x and y is greater than zero.
6. (previously presented) A compound according to claim 5, or a salt thereof, wherein A¹ is an aryl radical.
7. (previously presented) A compound according to claim 6 selected from the group consisting of: (1E)-2-(4-fluorophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; (1E)-2-(4-chlorophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; (1E)-2-(4-bromophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; (1E)-2-(2-nitrophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; (1E)-2-(3-nitrophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; and (1E)-2-(4-nitrophenyl)-1-[(naphthylmethyl)sulfinyl]ethene.
8. (previously presented) A compound according to claim 6, of Formula IB:



or a salt thereof.

9. (previously presented) A compound according to claim 8, or a salt thereof, wherein each R^a is independently selected from the group consisting of halogen, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, $-NO_2$, $-CN$, $-C(=O)OR^2$, $-OH$, $-NH_2$, (C_1-C_6) trifluoroalkoxy and $-CF_3$.
10. (currently amended) A compound according to claim 9 8, of Formula IC:



or a salt thereof.

11. (currently amended) A compound according to claim 10 wherein each R^a is independently selected from the group consisting of halogen, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, $-NO_2$, $-CN$ and $-CF_3$, and each R^b is independently selected from the group consisting of halogen, ~~(C_1-C_6) alkyl~~, (C_1-C_6) alkoxy, $-NO_2$, $-CN$ and $-CF_3$.
12. (previously presented) A compound according to claim 10, or a salt thereof, wherein the configuration of the substituents on the carbon-carbon double bond is *E*-.
13. (previously presented) A compound according to claim 12, or a salt thereof, wherein x is 0, 1 or 2 and y is 1 or 2.
14. (currently amended) A compound according to claim 12 selected from the group consisting of: (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl) ethene; (1E)-1-{[(3-hydroxy-4-methoxyphenyl)methyl]sulfinyl}-2-

(2,4,6-trimethoxyphenyl) ethene; (1E)-1-{[(4-methoxy-3-nitrophenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl) ethene; 2-({[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]amino} sulfonyl)acetic acid; 2-{N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}acetic acid; [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]aminocarboxamidine; 2-{[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]amino}acetic acid; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](3,5-dinitrophenyl)carboxamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](3,5-diaminophenyl)carboxamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-chloroacetamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(4-methylpiperazinyl)acetamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]benzamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl](4-nitrophenyl)carboxamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](4-aminophenyl)carboxamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](2R)-2,6-diaminohexanamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](2R)-2-amino-3-hydroxypropanamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](2S)-2-amino-3-hydroxypropanamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]aminamide; (1E)-1-({[4-methoxy-3-(methylamino)phenyl]methyl}sulfinyl)-2-(2,4,6-trimethoxyphenyl)ethene; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]acetamide; [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][(2,4-dinitrophenyl)sulfonyl]amine; [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][(2,4-diaminophenyl)sulfonyl]amine; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(dimethylamino)-

acetamide; 2-{[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]amino}propanoic acid; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][4-(4-methylpiperazinyl)phenyl]carboxamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-hydroxyacetamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-pyridylacetamide; {*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}methyl acetate; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-hydroxypropanamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(triethylamino)acetamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-[tris(2-hydroxyethyl)amino]acetamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-hydroxy-2-methylpropanamide; 1-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}-isopropyl acetate; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2,2,2-trifluoroacetamide; [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][(trifluoromethyl)sulfonyl]amine; 3-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}propanoic acid; 3-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}propanoyl chloride; 3-{[*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}methyloxycarbonyl}propanoic acid; 4-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}butanoic acid; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(phosphonoxy)acetamide, disodium salt; 4-{[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]amino}butanoic acid; 3-{[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]amino}propanoic acid; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]methoxycarboxamide; [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][(4-methoxyphenyl)sulfonyl]amine; {*N*-

[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}ethyl acetate; methyl-3-{N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]-sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}propanoate; ethyl-2-{N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}acetate; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2,2,3,3,3-pentafluoropropanamide; methyl-2-{N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]-sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}-2,2-difluoroacetate; 3-{N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}-2,2,3,3-tetrafluoropropanoic acid; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-aminoacetamide; 2-{N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}-2,2-difluoroacetic acid; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(dimethylamino)-2,2-difluoroacetamide, 4-((1E)-2-{{[(4-fluorophenyl)methyl]sulfinyl}vinyl})benzoic acid; 4-((1E)-2-{{[(4-iodophenyl)methyl]sulfinyl}vinyl})benzoic acid; 4-((1E)-2-{{[(4-chlorophenyl)methyl]sulfinyl}vinyl})benzoic acid; 1-[5-((1E)-2-{{[(4-chlorophenyl)methyl]sulfinyl}vinyl})-2-fluoro-phenyl]-2-(dimethylamino)ethan-1-one; (1E)-2-(2,4-difluorophenyl)-1-{{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-amino-4-fluorophenyl)-1-{{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-1-{{[(4-fluorophenyl)methyl]sulfinyl}-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-1-{{[(4-chlorophenyl)methyl]sulfinyl}-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-1-{{[(4-bromophenyl)methyl]sulfinyl}-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-2-(4-fluorophenyl)-1-{{[(2,3,4,5,6-pentafluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-chlorophenyl)-1-{{[(2,3,4,5,6-pentafluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-bromophenyl)-1-{{[(2,3,4,5,6-pentafluorophenyl)methyl]sulfinyl}ethene; (1E)-1-{{[(3,4-dichlorophenyl)methyl]sulfinyl}-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-1-{{[(4-iodophenyl)methyl]sulfinyl}-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-1-{{[(4-fluorophenyl)methyl]sulfinyl}-2-(2-hydroxy-3,5-dinitrophenyl)ethene; (1E)-1-{{[(4-bromophenyl)methyl]sulfinyl}-2-(2-hydroxy-3,5-

- 11 -

- 12 -

phenyl)methyl]sulfinyl}-ethene; (1E)-2-(3-nitrophenyl)-1-{{(4-fluorophenyl)methyl]-sulfinyl}-ethene; (1E)-2-(4-nitrophenyl)-1-{{(4-fluorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(2-trifluoromethylphenyl)-1-{{(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-trifluoromethylphenyl)-1-{{(4-fluorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(4-trifluoromethylphenyl)-1-{{(4-fluorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(2-trifluoromethyl-4-fluorophenyl)-1-{{(4-fluorophenyl)-methyl]sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{{(4-chlorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(3-nitrophenyl)-1-{{(4-chlorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(4-nitrophenyl)-1-{{(4-chlorophenyl)-methyl]sulfinyl}-ethene; (1E)-2-(2-trifluoromethylphenyl)-1-{{(4-chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(3-trifluoromethylphenyl)-1-{{(4-chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(4-trifluoromethylphenyl)-1-{{(4-chlorophenyl)-methyl]sulfinyl}ethene; (1E)-2-(2-trifluoromethyl-4-fluorophenyl)-1-{{(4-chlorophenyl)-methyl]sulfinyl}ethene; ~~(1E)-2-(3-methyl-4-fluorophenyl)-1-{{(4-chlorophenyl)methyl]-sulfinyl}ethene;~~ (1E)-2-(2-nitrophenyl)-1-{{(2,4-dichlorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(2-trifluoromethyl-4-fluorophenyl)-1-{{(2,4-dichloro-phenyl)methyl]sulfinyl}-ethene; (1E)-2-(2-nitrophenyl)-1-{{(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-nitrophenyl)-1-{{(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-nitrophenyl)-1-{{(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-trifluoromethylphenyl)-1-{{(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-trifluoromethylphenyl)-1-{{(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-trifluoromethylphenyl)-1-{{(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{{(4-cyanophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-nitrophenyl)-1-{{(4-cyanophenyl)-methyl]sulfinyl}ethene; (1E)-2-(4-nitrophenyl)-1-{{(4-cyanophenyl)-methyl]sulfinyl}ethene; (1E)-2-(4-fluorophenyl)-1-{{(4-methylphenyl)methyl]sulfinyl}-ethene; (1E)-2-(4-bromophenyl)-1-{{(4-methylphenyl)methyl]sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{{(4-methylphenyl)methyl]sulfinyl}ethene; (1E)-2-(3-nitrophenyl)-1-{{(4-methylphenyl)methyl]sulfinyl}ethene; (1E)-2-(4-nitrophenyl)-1-{{(4-methylphenyl)methyl]sulfinyl}ethene; (1E)-2-(4-fluorophenyl)-1-{{(4-methoxyphenyl)methyl]sulfinyl}ethene; (1E)-2-(4-chlorophenyl)-1-{{(4-

methoxyphenyl)methyl]-sulfinyl}ethene; (1E)-2-(4-bromophenyl)-1-{[(4-methoxyphenyl)methyl]-sulfinyl}ethene;
 methoxyphenyl)methyl]-sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{[(4-methoxyphenyl)methyl]sulfinyl}ethene;
 methoxyphenyl)methyl]sulfinyl}ethene; (1E)-2-(3-nitrophenyl)-1-{[(4-methoxyphenyl)methyl]sulfinyl}ethene;
 methoxyphenyl)methyl]sulfinyl}ethene; (1E)-2-(4-nitrophenyl)-1-{[(4-methoxyphenyl)methyl]sulfinyl}ethene;
 (1E)-2-(4-chlorophenyl)-1-{[(4-nitrophenyl)methyl]-sulfinyl}ethene; (1E)-2-(4-fluorophenyl)-1-{[(4-nitrophenyl)methyl]sulfinyl}ethene; and salts thereof.

15. (currently amended) A compound according to claim 10 wherein:

R^a is selected from the group consisting of chlorine, fluorine and bromine, and said R^a is bonded to the para position of the ring to which it is attached;

x is 0 or 1;


R^b is selected from the group consisting of chlorine, fluorine, bromine, methyl and methoxy, and said R^b is bonded to the ortho or para position of the ring to which it is bonded; and

y is 1, 2 or 3.

16. (previously presented) A compound according to claim 15 wherein the configuration of the substituents on the carbon-carbon double bond is *E*-.

17. (previously presented) A compound according to claim 16 selected from the group consisting of: (1E)-2-(2-chlorophenyl)-1-[benzylsulfinyl]ethene; (1E)-2-(4-chlorophenyl)-1-[benzylsulfinyl]ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(4-fluorophenyl)ethene; (1E)-2-(4-chlorophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(4-fluorophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2,4-difluorophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-fluorophenyl)ethene; (1E)-2-(4-bromophenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-bromophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; and (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-chlorophenyl)ethene.

- 15 -



wherein B² is selected from the group consisting of heteroaryl and aryl other than phenyl

or a salt thereof.

22. (previously presented) A compound according to claim 21, or a salt thereof, wherein B² is heteroaryl.
23. (currently amended) A compound according to claim 21, or a salt thereof, wherein B² is selected from the group consisting of furyl, thienyl, pyrrolyl, thiazolyl, pyridyl, thienyl-1,1-dioxide, anthryl, and naphthyl.
24. (previously presented) A compound according to claim 23, or a salt thereof, wherein the configuration of the substituents on the carbon-carbon double bond is *E*-.
25. (previously presented) A compound according to claim 24, or a salt thereof, wherein R^a is independently selected from the group consisting of halogen, (C₁-C₃)alkoxy, -CN, -NO₂, and -CF₃.
26. (original) A compound of claim 25 selected from the group consisting of: (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(2-pyridyl)ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(3-pyridyl)ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(4-pyridyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2-pyridyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(3-pyridyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(4-pyridyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(2-pyridyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(3-pyridyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-

pyridyl)ethene; (1E)-1-{{(4-fluorophenyl)methyl}sulfinyl}-2-(2-thienyl)ethene; (1E)-1-
 {{(4-chlorophenyl)methyl}sulfinyl}-2-(2-thienyl)ethene; (1E)-1-{{(4-
 bromophenyl)methyl}sulfinyl}-2-(2-thienyl)ethene; (1E)-2-(4-bromo(2-thienyl))-1-{{(4-
 fluorophenyl)methyl}sulfinyl}ethene; (1E)-2-(5-bromo(2-thienyl))-1-{{(4-
 fluorophenyl)methyl}sulfinyl}ethene; (1E)-2-(5-bromo(2-thienyl))-1-{{(4-
 chlorophenyl)methyl}sulfinyl}ethene; (1E)-2-(5-bromo(2-thienyl))-1-{{(4-
 bromophenyl)methyl}sulfinyl}ethene; 2-((1E)-2-{{(4-
 fluorophenyl)methyl}sulfinyl}vinyl)thiole-1,1-dione; 2-((1E)-2-{{(4-chlorophenyl)-
 methyl}sulfinyl}vinyl)thiole-1,1-dione; 2-((1E)-2-{{(4-bromophenyl)methyl]-
 sulfinyl}vinyl)thiole-1,1-dione; (1E)-1-{{(4-fluorophenyl)methyl}sulfinyl}-2-(3-
 thienyl)ethene; (1E)-1-{{(4-chlorophenyl)methyl}sulfinyl}-2-(3-thienyl)ethene; (1E)-1-
 {{(4-bromophenyl)methyl}sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{{(4-
 iodophenyl)methyl}sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{{(4-
 methylphenyl)methyl}sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{{(4-methoxyphenyl)-
 methyl}sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{{(4-trifluoromethylphenyl)methyl]-
 sulfinyl}-2-(3-thienyl)-ethene; (1E)-1-{{(2,4-dichlorophenyl)methyl}sulfinyl}-2-(3-
 thienyl)-ethene; (1E)-1-{{(3,4-dichlorophenyl)methyl}sulfinyl}-2-(3-thienyl)-ethene;
 (1E)-1-{{(4-cyanophenyl)methyl}sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{{(4-
 nitrophenyl)methyl}sulfinyl}-2-(3-thienyl)ethene; 3-((1E)-2-{{(4-
 fluorophenyl)methyl}sulfinyl}vinyl)thiole-1,1-dione; 3-((1E)-2-{{(4-
 chlorophenyl)methyl}sulfinyl}vinyl)thiole-1,1-dione; 3-((1E)-2-{{(4-bromophenyl)-
 methyl}sulfinyl}vinyl)thiole-1,1-dione; 3-((1E)-2-{{(4-methoxyphenyl)-
 methyl}sulfinyl}vinyl)thiole-1,1-dione; 3-((1E)-2-{{(2,4-dichlorophenyl)methyl]-
 sulfinyl}vinyl)thiole-1,1-dione; (1E)-1-{{(4-fluorophenyl)methyl}sulfinyl}-2-(2-
 furyl)ethene; (1E)-1-{{(4-chlorophenyl)methyl}sulfinyl}-2-(2-furyl)ethene; (1E)-1-{{(4-
 bromophenyl)methyl}sulfinyl}-2-(2-furyl)ethene; (1E)-1-{{(4-
 fluorophenyl)methyl}sulfinyl}-2-(3-furyl)ethene; (1E)-1-{{(4-chlorophenyl)-
 methyl}sulfinyl}-2-(3-furyl)ethene; (1E)-1-{{(4-bromophenyl)methyl}sulfinyl}-2-(3-
 furyl)ethene; (1E)-1-{{(4-iodophenyl)methyl}sulfinyl}-2-(3-furyl)ethene; (1E)-1-{{(4-

methylphenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{{(4-methoxyphenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{{(4-trifluoromethylphenyl)methyl]sulfinyl}-2-(3-furyl)-ethene; (1E)-1-{{(2,4-dichlorophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{{(3,4-dichlorophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{{(4-cyanophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{{(4-nitrophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{{(4-chlorophenyl)methyl]sulfinyl}-2-(1,3-thiazol-2-yl)-ethene; (1E)-1-{{(4-chlorophenyl)methyl]sulfinyl}-2-pyrrol-2-ylethene; (1E)-1-{{(4-bromophenyl)methyl]sulfinyl}-2-pyrrol-2-ylethene; (1E)-1-{{(4-chlorophenyl)methyl]sulfinyl}-2-(5-nitro(3-thienyl))ethene; (1E)-1-{{(4-iodophenyl)methyl]sulfinyl}-2-(5-nitro(3-thienyl))ethene; (1E)-1-{{(2,4-dichlorophenyl)methyl]sulfinyl}-2-(5-nitro(3-thienyl))ethene; (1E)-1-{{(4-methoxyphenyl)methyl]sulfinyl}-2-(5-nitro(3-thienyl))ethene; (1E)-1-{{(4-fluorophenyl)methyl]sulfinyl}-2-naphthylethene; (1E)-1-{{(4-fluorophenyl)methyl]sulfinyl}-2-(2-naphthyl)ethene; (1E)-1-{{(4-chlorophenyl)methyl]sulfinyl}-2-naphthylethene; (1E)-1-{{(4-chlorophenyl)methyl]sulfinyl}-2-(2-naphthyl)ethene; (1E)-1-{{(4-bromophenyl)methyl]sulfinyl}-2-naphthylethene; (1E)-1-{{(4-bromophenyl)methyl]sulfinyl}-2-(2-naphthyl)ethene; (1E)-2-(9-anthryl)-1-{{(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(9-anthryl)-1-{{(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(9-anthryl)-1-{{(4-bromophenyl)methyl]sulfinyl}ethene; and salts thereof.

27. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

28. (withdrawn – currently amended) A conjugate of the Formula, $I-L-Ab$ IC-L-Ab; wherein:

I IC is a compound according to claim I 10 or a pharmaceutically acceptable salt thereof;

Ab is an antibody; and

—L— is a single covalent bond or a linking group covalently linking said compound to said antibody.

29. (withdrawn) A conjugate according to claim 28 wherein said antibody Ab is a monoclonal antibody or a monospecific polyclonal antibody.
30. (withdrawn) A conjugate according to claim 29 wherein said antibody Ab is a tumor-specific antibody.
31. (withdrawn) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one conjugate according to claim 28.
32. (currently amended) A method of treating an individual for breast cancer, prostate cancer, lung cancer or colorectal cancer comprising administering to said individual in need of such treatment an effective amount of a compound according to claim + 10, or a pharmaceutically acceptable salt thereof.
33. (canceled)
34. (canceled)
35. (canceled)
36. (currently amended) A method of treating an individual for a cancer selected from the group consisting of breast, prostate, lung, and colorectal cancers, comprising administering to said individual an effective amount of a compound according to claim + 10, or a pharmaceutically acceptable salt thereof, and administering an effective amount of therapeutic ionizing radiation to the individual.
37. (currently amended) A method of inducing apoptosis of tumor cells in an individual afflicted with breast cancer, prostate cancer, lung cancer or colorectal cancer comprising

administering to said individual an effective amount of a compound according to claim 4
10, or a pharmaceutically acceptable salt thereof.

38. (canceled)

39. (withdrawn) A method of treating an individual afflicted with breast cancer, prostate cancer, lung cancer or colorectal cancer, comprising administering to said individual an effective amount of at least one conjugate according to claim 28.

40. (canceled)

41. (canceled)

42. (canceled)

43. (canceled)

44. (canceled)

45. (canceled)

46. (canceled)

47. (canceled)

48. (canceled)

49. (canceled)

50. (canceled)

51. (canceled)

52. (canceled)

53. (canceled)

54. (canceled)

55. (canceled)

56. (canceled)

57. (canceled)

58. (canceled)

59. (canceled)

60. (canceled)

61. (canceled)

62. (canceled)

63. (canceled)

64. (canceled)


65. (canceled)

66. (canceled)

67. (canceled)

68. (canceled)

69. (currently amended) A process for preparing a compound according to claim 3 of Formula Ia:



wherein:

A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

B is substituted aryl or substituted or unsubstituted heteroaryl;


n is 1;

R¹ is -H, -(C₁-C₈)hydrocarbyl, -CN, -CO₂(C₁-C₆)alkyl or halo(C₁-C₆)alkyl;

the configuration of the substituents on the sulfoxide sulfur atom is R-, S- or any mixture of R- and S-;

* indicates that, when R¹ is other than -H, the configuration of the substituents on the designated carbon atom is R-, S- or any mixture of R- and S-; or a salt of such a compound, comprising:

(a) reacting a compound of Formula II:




wherein A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

n is 1; and

R¹ is -H, -(C₁-C₈)hydrocarbyl, -CN, -CO₂(C₁-C₆)alkyl or halo(C₁-C₆)alkyl;

with a compound of Formula III:




wherein B is substituted aryl or substituted or unsubstituted heteroaryl; and

(b) isolating a compound according to claim 3 of Formula 1e from the reaction products.

70. (withdrawn) A process according to claim 69 wherein the compound of Formula II is prepared by;

(a) reacting a compound of Formula IIA:




with an oxidizing agent capable of oxidizing a sulfide to a sulfoxide; and

(b) isolating a compound of Formula II from the reaction products.

71. (withdrawn) A process according to claim 70 wherein the compound of Formula IIA is prepared by:

(a) reacting a compound of Formula IIB:




wherein:

L is a leaving group;

with mercaptoacetic acid; and

(b) isolating a compound of Formula IIA from the reaction products.

72. (withdrawn - currently amended) A process for preparing a compound according to claim 2 of Formula Iz:



wherein:

A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

B is substituted aryl or substituted or unsubstituted heteroaryl;


n is 1;

R¹ is -H, -(C₁-C₈)hydrocarbyl, -CN, -CO₂(C₁-C₆)alkyl or halo(C₁-C₆)alkyl;

the configuration of the substituents on the sulfoxide sulfur atom is R-, S- or any mixture of R- and S-;

* indicates that, when R¹ is other than -H, the configuration of the substituents on the designated carbon atom is R-, S- or any mixture of R- and S-; or a salt of such a compound, comprising:

(a) reacting a compound of Formula IV:



wherein:

A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

B is substituted aryl or substituted or unsubstituted heteroaryl;

n is 1; and


R¹ is -H, -(C₁-C₈)hydrocarbyl, -CN, -CO₂(C₁-C₆)alkyl or halo(C₁-C₆)alkyl;

with an oxidizing agent capable of oxidizing a sulfide to a sulfoxide; and

(b) isolating a compound according to ~~claim 2~~ of Formula Iz from the reaction products.


73. (withdrawn) A process according to claim 72 wherein the compound of Formula IV is prepared by:

(a) reacting a compound of Formula IVA:




wherein Q⁺ is a counterion selected from the group consisting of alkali metals, alkaline earth metals and transition metals;

with a compound of Formula IVB:



(b) isolating a compound of Formula IV from the reaction products.

74. (withdrawn) A process for preparing a compound according to Formula V:



wherein:

A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

B is substituted aryl or substituted or unsubstituted heteroaryl;

n is 1;


R¹ is -H, -(C₁-C₈)hydrocarbyl, -CN, -CO₂(C₁-C₆)alkyl or halo(C₁-C₆)alkyl;

the configuration of the substituents on the carbon-carbon double bond is either *E*- or *Z*-; and

* indicates that, when R¹ is other than -H, the configuration of the substituents on the designated carbon atom is R-, S- or any mixture of R- and S-; or a salt of such a compound;

comprising the steps of:

(a) reacting a compound according to Formula I:



wherein A, B, n, R¹ and * are so defined;

A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

the configuration of the substituents on the carbon-carbon double bond is either *E*- or *Z*-; and

the configuration of the substituents on the sulfoxide sulfur atom is R-, S- or any mixture of R- and S-; or a salt thereof;

with an oxidizing agent capable of oxidizing a sulfoxide to a sulfone; and

(b) isolating a compound according to Formula V from the reaction products.

75. (canceled)

76. (canceled)

77. (previously presented) An isolated optical isomer of a compound according to claim 1, or a salt thereof.